Samsung Biologics Co Ltd
- 取引所
- 韓国株
- 国 / 地域
- Korea
- 従業員数
- 5,195
- 公式サイト
- samsungbiologics.com
総合バリュエーションレンジ · 保守的 850,000–1,100,000 / 妥当 1,250,000–1,600,000 / 楽観的 1,900,000–2,300,000。1,430,000 時点で 妥当な本源的価値レンジ内。
レポート公開時 1,336,000(2026年6月5日)
この銘柄のレポートはお使いの言語でまだありません。
Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical testing services, such as IPC and release testing, stability study and testing, environmental monitoring, biosafety testing, as well as manufactures drug substance. In addition, it engages in the development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
データ提供:EODHD、報告通貨で表示。参考情報であり、投資助言ではありません。
沿革
近日公開このセクションは現在準備中です。近日公開予定です。
業界での地位
近日公開このセクションは現在準備中です。近日公開予定です。
